



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. F		ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/016,986	12/12/2001		Dennis R. Burton	TSRI 313.2 C1 6775		
26621	7590 05/19/2004			EXAM	EXAMINER	
		ARCH INSTITU	LI, BAO Q			
		COUNSEL, TPC-8 EY PINES ROAD	3	ART UNIT	PAPER NUMBER	
LA JOLLA,			1648			

DATE MAILED: 05/19/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>4</b>	Application No.	Applicant(s)				
	10/016,986	BURTON ET AL.				
Office Action Summary	Examiner	Art Unit				
•	Bao Qun Li	1648				
The MAILING DATE of this communication ap	•					
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a replection of the period for reply specified above, the maximum statutory period.  - Failure to reply within the set or extended period for reply will, by statute any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be timely within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONF.	nely filed s will be considered timely. the mailing date of this communication. D. (35 U.S.C. § 133)				
Status						
1) Responsive to communication(s) filed on 06 C	October 2003.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) ⊠ Claim(s) <u>1-30</u> is/are pending in the application 4a) Of the above claim(s) is/are withdrays 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-30</u> are subject to restriction and/or	wn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b) objected to by the Education of the Education of the drawing (s) be held in abeyance. See tion is required if the drawing (s) is objection is	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Application rity documents have been receive u (PCT Rule 17.2(a)).	on No d in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	PTO-413)					
<ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ul>	Paper No(s)/Mail Dai 5) Notice of Informal Pa 6) Other:					

Application/Control Number: 10/016,986

Art Unit: 1648

12 1

## **DETAILED ACTION**

Claims 1-30 are pending.

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-11, 29 and 30, drawn to a monoclonal antibody and a composition and a kit comprising the antibody, classified in class 424, subclass 131.1.
  - II. Claims 12-14 drawn to drawn to polynucleotide, a host cell and a vector comprising the same, classified in class 536, subclass 23.4.
  - III. Claim 15, drawn to a method of determining an antibody, classified in class 435, subclass 7.1.
  - IV. Claims 16-19, drawn to a method of detecting HIV, classified in class 435, subclass 5.
  - V. Claims 22-28, drawn to a method for providing a passive immunotherapy, classified in class 424, subclass 93.2.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions Group I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of group I and II are directed to structurally different produces, e.g. the product of group I is a monoclonal antibody, whereas the product of group II is a nucleic acid.
- 3. Inventions of group I and III-V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the process for using the product as claimed can be practiced with another materially different product. For example, the method of Group IV can be practiced with a nucleic acid sequences for doing PCR rather than an antigen biding to antibody immunoassay.

Page 3

Application/Control Number: 10/016,986

Art Unit: 1648

£.,

Because these inventions are distinct for the reasons given above and the search required 4. for Group I is not required for Group II, restriction for examination purposes as indicated is proper.

- 5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- Applicant is reminded that upon the cancellation of claims to a non-elected invention, the 6. inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao Qun Li whose telephone number is 571-272-0904. The examiner can normally be reached on 7:00 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 571-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bao Qun Li

Art Unit 1648

May 17, 2004

SUPERVISORY PATENT EXAMINER **TECHNOLOGY CENTER 1600**